Outcome of RI-CBT
| Patient no. . | Neutrophil engraftment, d . | Platelet engraftment, d . | Pre-engraftment immune reactions* . | aGVHD 2-4 . | aGVHD 3-4 . | cGVHD . | Survival . | Survival from transplantation, d . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 27 | 52 | No | Yes | No | No | Dead | 1264 | Relapse |
| 2 | 22 | 54 | Yes | No | No | NE | Alive | 1672 | NA |
| 3 | 23 | Not engrafted | Yes | Yes | Yes | NE | Dead | 68 | Infection |
| 4 | 40 | 102 | Yes | Yes | No | Limited | Alive | 1481 | NA |
| 5 | 18 | 44 | Yes | No | No | No | Dead | 344 | Relapse |
| 6 | 14 | Not engrafted | Yes | No | No | NE | Dead | 78 | Relapse |
| 7 | 21 | 57 | Yes | Yes | Yes | Limited | Alive | 937 | NA |
| 8 | Not engrafted | Not engrafted | No | No | No | NE | Dead | 42 | Infection |
| 9 | 37 | Not engrafted | Yes | No | No | NE | Dead | 45 | MOF |
| 10 | 28 | Not engrafted | Yes | Yes | Yes | NE | Dead | 64 | GVHD |
| 11 | 27 | Not engrafted | Yes | No | No | NE | Dead | 61 | Relapse |
| 12 | 43 | NA | No | No | No | Limited | Alive | 392 | NA |
| 13 | 21 | 47 | No | No | No | Limited | Alive | 355 | NA |
| 14 | 20 | 50 | No | No | No | NE | Dead | 100 | Relapse |
| Patient no. . | Neutrophil engraftment, d . | Platelet engraftment, d . | Pre-engraftment immune reactions* . | aGVHD 2-4 . | aGVHD 3-4 . | cGVHD . | Survival . | Survival from transplantation, d . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 27 | 52 | No | Yes | No | No | Dead | 1264 | Relapse |
| 2 | 22 | 54 | Yes | No | No | NE | Alive | 1672 | NA |
| 3 | 23 | Not engrafted | Yes | Yes | Yes | NE | Dead | 68 | Infection |
| 4 | 40 | 102 | Yes | Yes | No | Limited | Alive | 1481 | NA |
| 5 | 18 | 44 | Yes | No | No | No | Dead | 344 | Relapse |
| 6 | 14 | Not engrafted | Yes | No | No | NE | Dead | 78 | Relapse |
| 7 | 21 | 57 | Yes | Yes | Yes | Limited | Alive | 937 | NA |
| 8 | Not engrafted | Not engrafted | No | No | No | NE | Dead | 42 | Infection |
| 9 | 37 | Not engrafted | Yes | No | No | NE | Dead | 45 | MOF |
| 10 | 28 | Not engrafted | Yes | Yes | Yes | NE | Dead | 64 | GVHD |
| 11 | 27 | Not engrafted | Yes | No | No | NE | Dead | 61 | Relapse |
| 12 | 43 | NA | No | No | No | Limited | Alive | 392 | NA |
| 13 | 21 | 47 | No | No | No | Limited | Alive | 355 | NA |
| 14 | 20 | 50 | No | No | No | NE | Dead | 100 | Relapse |
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; NE, not evaluable; NA, not applicable; and MOF, multiple organ failure.
Pre-engraftment immune reactions were diagnosed when febrile patients developed skin eruption, diarrhea, jaundice, or body weight gain of more than 10% of baseline, with no direct evidence of infection or adverse effects of medication, developing more than 6 days before engraftment.18